The Problem: No Governance Means No Scale
The EU AI Act classifies many pharmaceutical AI applications as high-risk, requiring conformity assessments, human oversight mechanisms, and transparency documentation. Swiss regulations add additional requirements through nDSG and Swissmedic guidance. Without proactive governance, pharmaceutical companies face regulatory penalties, reputational damage, and — most commonly — AI programs stalled in perpetual pilot because no one has defined the rules for production deployment.
The Solution: Governance as Enablement, Not Bureaucracy
Effective governance isn't bureaucracy — it's enablement. A well-designed framework accelerates AI deployment by providing clear guardrails that development teams can follow confidently, reducing the cycle of ad-hoc review and rework that plagues ungoverned AI programs.
The Approach: Risk-Based, Regulation-Aligned Framework
- AI risk classification aligned with EU AI Act categories
- Model validation and performance monitoring standards adapted from GAMP 5
- Bias detection and mitigation protocols for clinical and commercial AI
- Explainability requirements calibrated to use case risk level
- Human oversight mechanisms for high-stakes decisions
- Incident response and model rollback procedures
How ANG Associates Can Help
ANG Associates designs and implements AI governance frameworks tailored to pharmaceutical organizations. We understand the intersection of EU AI Act requirements, Swiss nDSG compliance, and GxP validation principles — and we translate these into practical governance structures that your teams can actually follow. Our delivery management approach ensures governance is embedded into your AI development lifecycle from the start, not bolted on as an afterthought.